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Highly prevalent colorectal cancer-infiltrating
LAPþ Foxp3 T cells exhibit more potent
immunosuppressive activity than Foxp3þ
regulatory T cells
M Scurr1, K Ladell1, M Besneux1, A Christian2, T Hockey2, K Smart1, H Bridgeman1,
R Hargest3, S Phillips3, M Davies3, D Price1, A Gallimore1,4 and A Godkin1,4
Although elevated CD4þFoxp3þ regulatory Tcell (Treg) frequencies within tumors are well documented, the functional
and phenotypic characteristics of CD4þFoxp3þ and CD4þFoxp3 Tcell subsets frommatched blood, healthy colon,
and colorectal cancer require in-depth investigation. Flow cytometry revealed that the majority of intratumoral
CD4þFoxp3þ Tcells (Tregs) were Heliosþ and expressed higher levels of cytotoxic T-lymphocyte antigen 4 (CTLA-4)
and CD39 than Tregs from colon and blood. Moreover,B30% of intratumoral CD4þFoxp3 Tcells expressed markers
associated with regulatory functions, including latency-associated peptide (LAP), lymphocyte activation gene-3 (LAG-
3), and CD25. This unique population of cells produced interleukin-10 (IL-10) and transforming growth factor-b (TGF-b),
andwasB50-foldmoresuppressive thanFoxp3þ Tregs.Thus, intratumoral Tregsarediverse, posingmultipleobstacles
to immunotherapeutic intervention in colorectal malignancies.
INTRODUCTION
Colorectal cancer (CRC) is the third and second most
commonly diagnosed malignancy in males and females,
respectively, with 1.2 million individual diagnoses and over
600,000 deaths worldwide each year.1 Where possible, a
colectomy to remove the primary tumor is performed; however,
40–50% of these patients will relapse or die from metastatic
disease, despite the use of adjuvant chemotherapy.
The adaptive immune system can be directed against
neoplastic, transformed cells.2 Although there is evidence that
an increasedCD3þ T cell infiltrate improves prognosis inCRC,3
the fact that tumors still progress demonstrates a failure of
antitumor immune responses to control the lesion effectively.
Immunologically, there are several explanations that may work
singularly or in conjunction to explain this observation. The
tumor microenvironment seems to suppress immune responses
as the tumor progresses, potentially reflecting a functional
switch in tumor-infiltrating dendritic cells toward an
immunosuppressive phenotype.4 This switch is encouraged
by suppressive cytokines and growth factors producedwithin the
tumor, including interleukin-10 (IL-10),5 transforming growth
factor-b (TGF-b),6 vascular endothelial growth factor,7 and the
activity of indoleamine 2,3-dioxygenase.8 Hence, antitumor T
cells become less responsive in advanced tumors.9
In addition to these factors, an antigen-specific suppression
of effector T cell responses is mediated by a population of
CD4þFoxp3þ regulatory T cells (Tregs),10,11 either directly or
through indirect effects on dendritic cells.12,13 These Tregs have
an important role in preventing autoimmunity, but may also
control immune responses in a range of tumors.14 We have
previously found that the presence of CRC is associated with an
expanded and distinct population of Tregs in blood, which
specifically inhibits antitumor immune responses.15 Resection
of the primary tumor led to a reduction in themagnitude of this
peripheral Treg population, and preoperative suppression of
tumor-specific T cell function was associated with tumor
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recurrence 1 year later.16 However, a number of reports have
demonstrated decreased Foxp3þ Treg infiltrates in more
advanced tumors that correlate with disease outcome.17,18
Differences in the proportions of peripheral and intratumoral
Foxp3þ Tregs could account for these seemingly disparate
findings, but it is also possible that Treg populations other than
Foxp3þ Tregs mediate suppression of antitumor responses.
To understand the role of intratumoral Tregs, we undertook
a detailed phenotypic and functional analysis of all CD4þ
T cell subsets that infiltrate colorectal tumors. We used
multiparameter flow cytometry and functional assays of
distinct populations isolated by fluorescence-activated cell
sorting (FACS) to compare tumor-infiltrating lymphocytes
(TILs) with the corresponding CD4þ T cell subsets in healthy
colon and peripheral blood. A marked difference in the
phenotype of Foxp3þ Tregs was observed, with intratumoral
Tregs expressing far greater levels of markers associated with
suppression, such as CD39 and cytotoxic T-lymphocyte
antigen 4 (CTLA-4). Furthermore, we identified a major
regulatory TIL population of CD4þLAPþ T cells that
coexpressed lymphocyte activation gene-3 (LAG-3) and
CD25, but not Foxp3 (forkhead box P3). These cells were
B50-foldmore potent at suppressing effector T cells compared
with conventional CD4þFoxp3þ T cells, and they did so
through the secretion of immunosuppressive cytokines. These
data reveal the presence of a novel suppressive CD4þ T cell
population within colorectal tumors that is phenotypically and
functionally distinct from CD4þFoxp3þ T cells.
RESULTS
The majority of CD4þFoxp3þ Tregs in colorectal tumors
are thymus derived and express ICOS
The Treg transcription factor Foxp3 is readily detected by flow
cytometry (Figure 1a). Compared with healthy age-matched
controls, the overall proportion of CD4þ T cells expressing
Foxp3 in the peripheral blood of CRC patients (n¼ 14) was
increased (patients 10.83±0.67% vs. controls 7.77±0.68%,
P¼ 0.014; Figure 1b). The relative proportions of Foxp3þ T
cells remained remarkably consistent in CRC patients between
peripheral blood and unaffected background colonic tissue
(blood 10.83±0.67% vs. colon 10.60±0.83%); however, a
significant increase was observed among colorectal tumor-
infiltrating CD4þ T cells (tumor 22.44±2.38%; P¼ 0.0004 vs.
colon, P¼ 0.0009 vs. blood).
We reported previously that conversion of effector T cells into
Tregs does not account for the increased proportion of Tregs
found in amurine tumormodel.19 Helios, a member of the Ikaros
family of transcription factors, has been identified as a marker of
thymus-derived Tregs,20 although several groups have recently
disputed this.21,22 Notably, we have found higher mean
fluorescence intensities of Foxp3 on Heliosþ Tregs
(Supplementary Figure S1 online), indicative of greater
suppressive potential.23 Most Foxp3þ Tregs in CRC patients
were Heliosþ , consistent with the notion that these populations
predominantly comprise naturally occurring Tregs (Figure 1c).
The proportion of intratumoral Foxp3þ Tregs that expressed
Helios was slightly lower compared with the corresponding
peripheral blood populations, however, suggesting that the degree
of conversion may be slightly increased in the tumor (tumor
57.13±2.00% vs. blood 69.28±2.63%, P¼ 0.012). Nonetheless,
this difference was small, indicating that conversion does not
account for the substantial enrichment of Foxp3þ Tregs observed
in colorectal tumors. Based on the expression of Helios,
approximately half of the Tregs in unaffected colon specimens
appeared to be peripherally induced (colon 48.00±3.09% vs.
blood 69.28±2.63%, P¼ 0.0004). These findings are in line with
previous reports demonstrating that the conversion of Foxp3 T
cells into Foxp3þ T cells physiologically expands the
Treg repertoire in the gut.24 Overall, these data are consistent
with our previous findings in murine models indicating
that tumor-infiltrating Tregs comprised mainly the naturally
occurring Treg population.19 In order to verify these
findings, we attempted to stain samples with Neuropilin-1,
another marker that was recently postulated to be
selectively expressed on naturally occurring Tregs;25
however, we failed to detect any Neuorpilin-1þ CD4þ T cells
within the colonor colorectal tumors (SupplementaryFigureS2).
The inducible T-cell costimulator (ICOS) molecule is
expressed on activated T cells, and interactions with the ICOS
ligand enhance T cell proliferation, cytokine production, and
survival.26 ICOS is also expressed abundantly on CD4þ
CD25highFoxp3þ Tregs, particularly those found in tumors.27
We identified a similar pattern in CRC patients, whereby ICOS
was expressedmainly on CD4þFoxp3þ T cells compared with
CD4þFoxp3 T cells in blood, colon, and tumor (Figure 1d).
The low levels of ICOS expression on CD4þFoxp3 cells did
not differ significantly by site (blood 13.91±2.56% vs.
colon 16.24±4.07% vs. tumor 20.61±3.49%, P¼ 0.37).
However, in line with previous reports, CD4þFoxp3þ TILs
expressed significantly higher levels of ICOS than peri-
pheral blood CD4þFoxp3þ T cells (blood 45.46±2.58% vs.
colon 39.10±6.81% vs. tumor 60.78±4.42%, P¼ 0.039).
Furthermore, there was a strong correlation between Foxp3
expression and ICOS expression on CD4þ TILs (P¼ 0.004,
R2¼ 0.71; Figure 1e). Purified CD4þ ICOSþ T cells weremore
proliferative in response to stimulation with aCD3/28 beads
compared with the corresponding CD4þ ICOS T cells, a
finding that was paralleled by ex vivo Ki67 staining
(Supplementary Figure S3). Taken together, the expression
patterns of Foxp3, Helios, and ICOS delineate a population of
naturally occurring, highly proliferative Tregs that infiltrate
colorectal tumors.
CD4þFoxp3 and CD4þFoxp3þ T cells derived from
blood, healthy colon, and colorectal tumors are
phenotypically distinct
Next, we conducted a detailed phenotypic analysis of CD4þ T
cells using a panel of antibodies specific for the markers CD25,
CTLA-4, CD39, LAG-3, CD103, ICOS, and Ki67, many of which
are associated with natural Tregs.28 Representative flow cyto-
metry plots are shown in Supplementary Figure S4. Specifically,
we compared CD4þFoxp3þ and CD4þFoxp3 T cells from
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blood, healthy colon, and tumor (Figures 2a–f and Tables 1–3).
CD4þ T cells derived from each compartment expressed distinct
patterns of these phenotypicmarkers. Expression levels of several
markers, such as CTLA-4 and CD39, increased steadily on both
CD4þFoxp3þ and CD4þFoxp3 T cells when comparing
bloodwith healthy colon to tumor (Figures 2a–c).Manymarkers
associated with Tregs, such as the IL-2 receptor a-chain CD25
and CTLA-4, are also known to be present on activated T cells.29
Accordingly, this upregulation could reflect an altered state of
activation in these distinct colonic and tumoral niches. This is
illustrated by CD25 expression (Figure 2a), which remained
relatively stable onFoxp3þ T cells but was significantly increased
among Foxp3 T cells (blood 9.69±1.08% vs. colon
28.93±3.51%, P¼ 0.0009; blood vs. tumor 41.23±3.05%,
Po0.0001). Similarly, a greater proportion of intratumoral
CD4þFoxp3 T cells proliferate in comparison with blood and
colon, as denoted by Ki67 expression (blood 5.39±0.46% vs.
colon 7.37±1.43%, P¼ 0.27; blood vs. tumor 26.07±3.96%,
P¼ 0.0015; colon vs. tumor, P¼ 0.0039; Figure 2d). Reduced
levels of the IL-7 receptor CD127 and the anti-apoptotic protein
BCL-2 were also observed among the CD4þFoxp3 TILs
(Supplementary Figure S5). CTLA-4 (Figure 2b), which is an
important negative immunomodulator that decreases cellular
cytokine production and proliferation,30 followed a similar
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Figure 1 Ex vivo phenotypic analysis of regulatory CD4þFoxp3þ T cells in colorectal cancer (CRC) patients. (a) Representative bivariate flow
cytometry plots showing Foxp3 (forkhead box P3) expression on live CD4þ T cells obtained from matched peripheral blood, unaffected colon, and
colorectal tumor samples. (b) Percentage of liveCD4þ T cells expressing Foxp3 in peripheral bloodmononuclear cell (PBMC) samples (n¼6) from age-
matched healthy donors (HD; mean age, 71 years), and PBMC, unaffected colon, and tumor samples from CRC patients (n¼ 14; mean age, 72 years).
(c, d) Intracellular expression of the (c) Helios transcription factor and (d) cell surface expression of ICOS were assessed on CD4þFoxp3þ regulatory
T cell (Tregs; m) and CD4þFoxp3 T cells (’) isolated from blood (PBMC), unaffected colon, and tumor samples from CRC patients. Significant
differences are indicated: *Po0.05, ***Po0.001. (e) Linear regression comparing the percentage of intratumoral CD4þ T cells expressing inducible
T-cell costimulator (ICOS) with the percentage of intratumoral CD4þFoxp3þ Tregs.
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pattern of expression to CD25 (blood 5.54±1.77% vs. colon
28.03±7.66%, P¼ 0.024; blood vs. tumor 43.61±5.51%,
P¼ 0.0004). There was also a significant increase in CTLA-4
expression on intratumoral Foxp3þ Tregs (blood 51.34±6.91%
vs. colon 77.08±6.83%, P¼ 0.0052; blood vs. tumor
89.60±3.72%, P¼ 0.0002).
CD39 is an ectonucleotidase that, together with CD73, drives
catabolism of extracellular adenosine triphosphate (ATP),
resulting in the generation of adenosine, an immuno-
suppressive molecule often elevated in cancer tissue.31 Both
molecules are often expressed on Foxp3þ T cells, and
generation of adenosine by these cells is one of the means
by which intratumoral Tregs may enact their suppressive
function.31 We found that Foxp3þ Tregs displayed markedly
increased expression of CD39 in healthy colon and tumor
(blood 44.10±4.94% vs. colon 75.42±8.16%, P¼ 0.0003;
blood vs. tumor 90.83±4.53%, Po0.0001; Figure 2c).
However, as with CTLA-4, a marked and significant
increase in CD39 expression was also observed among
intratumoral Foxp3 T cells (blood 5.24±0.99% vs. colon
55.58±9.85%, P¼ 0.0011; blood vs. tumor 74.8±6.79%,
Po0.0001).
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Figure 2 Ex vivo phenotypic analysis of CD4þFoxp3þ and CD4þFoxp3 T cells in different compartments. Compiled flow cytometry data are shown
for expression of (a) CD25, (b) cytotoxic T-lymphocyte antigen 4 (CTLA-4), (c) CD39, (d) Ki67, (e) LAG-3 and (f) CD103 amongCD4þFoxp3þ Tregs (m)
and CD4þFoxp3 T cells (’) in matched blood (peripheral bloodmononuclear cells (PBMCs)), unaffected colon, and tumor samples. Foxp3, forkhead
boxP3.Significant differences are indicated: *Po0.05, **Po0.01, and ***Po0.001.Representative flowcytometry plots depicting thegating strategyare
shown in Supplementary Figure S2 online.
Table 1 Phenotypic overview of CD4þFoxp3þ / T cells
CTLA-4 LAP LAG-3 CD39 CD103 Ki67 CD25 Helios ICOS
Tumor CD4þFoxP3 þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ  þ
CD4þFoxP3þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ
Colon CD4þFoxP3 þ þ þ  þ þ þ þ  þ  þ
CD4þFoxP3þ þ þ þ þ  þ þ þ  þ þ þ þ þ þ þ
PBMC CD4þFoxP3         þ
CD4þFoxP3þ þ þ   þ þ  þ þ þ þ þ þ þ þ þ
Abbreviations: CTLA-4, cytotoxic T-lymphocyte antigen 4; Foxp3, forkhead box P3; LAG-3, lymphocyte activation gene-3; LAP, latency-associated peptide; ICOS, inducible
T-cell costimulator; PBMC, peripheral blood mononuclear cell.
 , Average expression o10% of cells.
þ , Average expression 10–24.9% of cells.
þ þ , Average expression 25–49.9% of cells.
þ þ þ , Average expression 450% of cells.
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Both CD4þFoxp3 and CD4þFoxp3þ tumor-infiltrating
T cells express the phenotypic markers LAG-3 and CD103
associated with regulatory cells
The marked increase in CD39, together with CD25 and CTLA-
4, in the Foxp3 population suggests a possible regulatory role
for these cells within the tumor environment. Accordingly, we
examined other markers associated with regulatory function,
including LAG-3, described recently as selectively denoting
human Tr1-type Tregs.32–34 Although expression of LAG-3
among CD4þFoxp3þ and CD4þFoxp3 T cells was
comparable (Figure 2e), intratumoral levels were markedly
increased on both CD4þFoxp3 TILs (blood 10.0±3.1% and
colon 11.44±3.74% vs. tumor 34.92±8.18%, P¼ 0.023) and
CD4þFoxp3þ Tregs (blood 7.24±1.56% and colon
12.69±2.49% vs. tumor 28.18±5.68%, P¼ 0.02). Almost all
CD4þLAG-3þ T cells were CD25þ (Figure 3c).
The aE integrin, CD103, binds to the receptor E-cadherin
and is thought to play a role in T cell retention within the gut;35
it has also been shown to denote populations of highly
suppressive CD25þ and CD25 T cells.36 In the cohort of
patients studied here, CD103 expression was elevated in
colorectal tumors, particularly within the CD4þFoxp3
population (blood 2.08±0.22% vs. colon 9.54±2.49%,
P¼ 0.022; blood and colon vs. tumor 34.83±8.06%,
P¼ 0.01; Figure 2f). Recent reports claim that CD103
expression is significantly increased on CRC-resident Tregs
compared with unaffected colon;37 however, despite a trend, we
did not find this to be the case (colon 5.56±1.50% vs. tumor
10.19±2.66%, P¼ 0.13).
In summary, we observed that a significant proportion of
intratumoral CD4þFoxp3 cells demonstrated a unique
phenotype characterized by high expression levels of molecules
predominantly associated with Tregs, including CD25, CD39,
CTLA-4, LAG-3, CD39, and CD103 (summarized in Figure 4
and Tables 1–3). This finding led us to investigate the
function of these CD4þFoxp3 cells and, specifically, to
determine whether they could contribute to intratumoral
immunosuppression.
Table 2 Phenotypic overview of CD4þ ICOSþ / T cells
Foxp3 LAG-3 CD39 CD103 Ki67 CD25 Helios LAP
Tumor CD4þ ICOS  þ þ þ þ þ þ þ þ þ þ þ  þ þ
CD4þ ICOSþ þ þ þ þ þ þ þ þ þ þ þ þ þ þ
Colon CD4þ ICOS  þ þ þ   þ  þ
CD4þ ICOSþ þ þ þ þ þ þ  þ þ þ þ
PBMC CD4þ ICOS        
CD4þ ICOSþ þ þ  þ þ  þ þ þ þ þ 
Abbreviations: Foxp3, forkhead box P3; LAG-3, lymphocyte activation gene-3; LAP, latency-associated peptide; ICOS, inducible T-cell costimulator; PBMC, peripheral blood
mononuclear cell.
 , Average expression o10% of cells.
þ , Average expression 10–24.9% of cells.
þ þ , Average expression 25–49.9% of cells.
þ þ þ , Average expression 450% of cells.
Table 3 Phenotypic overview of CD4þLAPþ / T cells
CTLA-4 Foxp3 LAG-3 CD39 CD103 Ki67 CD25 ICOS
Tumor
CD4þLAP þ þ þ þ þ  þ þ þ þ þ þ  þ
CD4þLAPþ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ
Colon
CD4þLAP þ þ þ  þ þ  þ  
CD4þLAPþ þ þ þ  þ þ þ  þ þ þ þ þ
PBMC
CD4þLAP þ       þ
CD4þLAPþ þ     þ þ þ þ þ þ
Abbreviations: CTLA-4, cytotoxic T-lymphocyte antigen 4; Foxp3, forkhead box P3; LAG-3, lymphocyte activation gene-3; LAP, latency-associated peptide; ICOS, inducible
T-cell costimulator; PBMC, peripheral blood mononuclear cell.
 , Average expression o10% of cells.
þ , Average expression 10–24.9% of cells.
þ þ , Average expression 25–49.9% of cells.
þ þ þ , Average expression 450% of cells.
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CD4þLAPþ TILs act as amajor regulatory T-cell subset via
the production of IL-10 and TGF-b
The latency-associated peptide (LAP) has recently been
described as a marker of Tregs in human peripheral blood
that are distinct from conventional Foxp3þ Tregs.38 We
examined LAP expression on CD4þFoxp3þ and CD4þ
Foxp3 T cells from blood, healthy colon, and tumor samples.
Although comparable levels were observed in peripheral blood,
LAP expression was markedly increased on both Foxp3þ
T cells (blood 3.56±0.63% vs. colon 16.59±1.18%, Po0.0001;
blood vs. tumor 24.96±3.01%, P¼ 0.0007) and Foxp3 T cells
(blood 2.15±0.56% vs. colon 17.72±2.13%, P¼ 0.0001; blood
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Figure 3 CD4þ T cells expressing latency-associated peptide (LAP) and lymphocyte activation gene-3 (LAG-3), but not forkhead box P3 (Foxp3), are
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Figure 4 Concatenated ex vivo phenotypic analysis of CD4þFoxp3þ and CD4þFoxp3 cells in different compartments. Pie charts show the
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vs. tumor 28.24±3.69%, P¼ 0.0007) in healthy colon and
tumor samples (Figure 3a and Supplementary Figure S6A).
This marked enrichment of CD4þLAPþ T cells was most
striking in early-stage Dukes’ A tumors (Figure 3b), although a
trend for more CD4þFoxp3LAPþ T cells present in the
periphery of patients with more advanced tumors was also
noted (Supplementary Figure S7), as previously described.39
The majority of CD4þLAPþ TILs coexpressed LAG-3,
CD25 (Figure 3c and Table 3), and PD-1 (pro-
grammed cell death protein 1; data not shown); in contrast,
o10% of the corresponding CD4þLAP cells expressed
LAG-3 and CD25. Of note, however, most CD4þLAPþ
TILs (4 85%) did not express Foxp3. Collectively, these
observations demonstrate that the CD4þLAPþ T cell subset
is largely distinct from conventional Foxp3þ Tregs and
significantly enriched in tumors compared with blood
(Figure 4).
Next, we stimulated TILs polyclonally with phorbol 12-
myristate 13-acetate and ionomycin. CD4þLAPþ T cells
isolated from peripheral blood produced no IL-10 or IL-17A
(Figure 5a), whereas in the colon, the comparable cell subset
produced significantly more IL-10 than CD4þLAP T cells
(Figure 5b). The largest amounts of IL-10 were produced by
CD4þLAPþ T cells isolated from the tumor, whereas minimal
IL-17A and no interferon-g induction was observed among
these cells (Figure 5c). CD4þLAPþ T cells also stained for
membrane-bound active TGF-b (Figure 5d), indicating that
LAP expression denotes populations of cells that produce TGF-
b, consistent with previous reports.40 Together, these data
support the premise that LAP expressiondenotes a population of
intratumoral CD4þFoxp3 cells with considerable immuno-
suppressive potential.
To assess the functional significance of LAP expression,
CD4þLAPþ and CD4þLAP T cells were purified from
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colorectal tumor samples by FACS (Supplementary Figure
S6C). Stimulation of the CD4þLAPþ population in vitro with
aCD3/CD28 beads revealed that nearly 90% of these cells were
capable of rapid cell division (Figure 5e); this stands in
marked contrast to the anergic phenotype described
for conventional Tregs in vitro,41 despite the high degree
of turnover seen in vivo.42 The ability of CD4þLAPþ and
CD4þLAP T cells to inhibit effector CD4þ T cell proli-
feration in vitro was assessed using standard suppressor assays
and compared with conventional Tregs, which were sorted as
CD4þCD25hiCD127lo T cells (Foxp3 expression 490%;
Supplementary Figure S6B). Autologous peripheral blood
mononuclear cell (PBMC)-derived CD4þCD25 T cells
(Foxp3 expression o5%) labeled with carboxyfluorescein
diacetate succinimidyl ester (CFSE) were used as targets in
these suppression assays, and co-cultured with isolated TIL
subsets at ratios of 1:1, 1:0.5, 1:0.1, and 1:0.01 (Figure 6a).
A direct comparison of CD4þLAPþ T cells, CD4þLAP T
cells, and conventional Tregs demonstrated that LAPþ TILs
were able to suppress target cell proliferationB50-fold more
potently than either of the other two subsets. Interestingly, the
CD4þLAP population could still suppress at higher ratios,
most likely because of the presence of Foxp3þ Tregs. The
suppressive effects of CD4þLAPþ TILs were mediated by
both TGF-b and IL-10, as addition of antibodies to block
either cytokine partially restored effector T-cell proliferation
levels (CD4þLAPþ TILs alone 19.6±3.5%, þ anti-TGF-b
6.9±2.3%, P¼ 0.040; þ anti-IL-10R 5.7±4.7%, P¼ 0.041;
Figure 6b). Even when CD4þLAPþ TILs were separated from
CFSE-labeled responder T cells by 0.4 mm transwell inserts,
significant levels of suppression were still observed (CD4þ
LAPþ TILs 25.5±6.7% vs. CD4þLAP TILs 3.7±3.7%,
P¼ 0.052; vs. CD4þLAP Colon 2.6±2.6%, P¼ 0.043; vs.
CD4þCD25hiCD127lo blood 0.3±0.3%, P¼ 0.032; Figure 6c).
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indicatedcell subset isolated fromblood, colon,or tumorwasadded to the top insert of the transwell.Cellswere left for 72hbeforeanalyzing forCFSEdilution
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This finding is consistent with a role for immunosuppressive
cytokines in mediating the inhibitory effects of CD4þLAPþ T
cells. Thus, tumor-derived CD4þ T cells expressing LAP are
highly immunosuppressive and represent a major regulatory
T cell population among TILs.
DISCUSSION
Adaptive immune responses can control tumors, as illustrated
by successful vaccination and adoptive immunotherapy
studies.43 However, many immunotherapy trials have shown
poor response rates, potentially because of the inhibition of
tumor-specific responses by immune regulatory networks.
A large body of data now associate increased frequencies
of CD4þFoxp3þ T cells (Tregs) with a range of tumors.14
Furthermore, Treg accumulation is linked with poor outcome
in several malignancies, including ovarian cancer44 and CRC.16
Previously, we showed that antitumor CD4þ T cell responses
were reduced in patients with CRC before resection of the
tumor; this phenomenon was related to Treg frequencies in
peripheral blood, defined initially by high levels of CD25
expression on CD4þ T cells,15 andmore recently by expression
of the transcription factor Foxp3.16
Despite substantial evidence indicating that regulatory T
cells impinge upon antitumor immune responses in patients
with cancer,10 many studies in humans have focused largely on
blood-derived Tregs. This raises the question of whether
intratumoral Tregs carry out the same function as those in
blood. Indeed, the role of colorectal tumor-infiltrating Tregs in
particular has been widely debated.45 Aberrant intratumoral
expression of Foxp3, which may not denote a homogenous
population of suppressive T cells, has been mooted as a reason
why Treg numbers seem to be high in early tumors with a better
prognosis.29,46,47 This apparent contradiction may be resolved
by ongoing clinical trials that deplete Foxp3þ Tregs in CRC
patients as a potential adjuvant to antitumor T cell stimulation.
Nonetheless, detailed insights into the complexity and function
of colorectal tumor-infiltrating T cell subsets are essential to
guide the rational manipulation of T cell responses for the
purpose of optimizing antitumor immunity.
Access to matched blood, healthy colon, and colorectal
tumor samples from multiple CRC patients enabled us to
conduct a detailed phenotypic comparison of CD4þ T cells
derived from these different compartments. The relative
proportion of CD4þ T cells that expressed Foxp3, conven-
tionally classified as Tregs, was significantly higher within
tumors compared with healthy colon. Expression of Helios was
confined to this Foxp3þ population, which was also highly
enriched for ICOS-expressing cells. However, an extensive
comparison of CD4þFoxp3þ and CD4þFoxp3 populations
revealed that the expression of other markers classically
associated with Tregs in peripheral blood, including CD25,
CTLA-4, CD39, and CD127, was less specific for intratumoral
Foxp3þ cells. These molecules are upregulated on effector
memory T cells during antigen-driven activation. Strikingly,
however, these intratumoral CD4þFoxp3 cells did not
express the activation marker ICOS, thereby suggesting that
their unique phenotypic profile was not solely the result of
T cell activation.
Expression of the ectonucleotidase CD39 suggested that
intratumoral CD4þFoxp3 T cells might exert a regulatory
role. This was further borne out by analyses of LAP and LAG-3
expression. Suppressive T cells that express LAP but not Foxp3
have previously been identified in humans.38 In addition, T cell
expression of the CD4 homolog and negative regulator, LAG-3,
has been shown to maintain tolerance to self and tumor
antigens by directly regulating CD8þ T cell effector func-
tion;48,49 synergy between LAG-3 with PD-1 on TILs has also
been shown to promote tumoral immune escape in a number of
tumor models.33 We detected a large proportion of CD4þ T
cells that expressed LAP, part of the membrane-bound latent
TGF-b complex; increased proportions of CD4þLAPþ T cells
among peripheral blood and tumor-infiltrating lymphocytes
have recently been described, but the functional analysis of
these cells was limited to blood-derived samples.39 In
agreement with this work, we found LAP was only expressed
on very small populations of T cells in the peripheral blood,
although this did increase with advancing tumor stage. T cell
expression of LAP was strongly associated with the tumor
microenvironment, particularly among early-stage Dukes’ A
tumors. In the case of these tumors, LAPþFoxp3 T cells
outnumbered both Foxp3þHeliosþ and Foxp3þHelios
cells, implying that at this stage in cancer progression, LAPþ
Foxp3 T cells are more prevalent than both naturally
occurring and induced Foxp3þ Tregs. These CD4þLAPþ
cells coexpressed LAG-3 in the tumor, but only a minority
expressed Foxp3, consistent with descriptions of LAG-3þ T
cells that infiltrate Hodgkin’s lymphomas and bear suppressive
activity without Foxp3 expression.50
Overall, the data presented here reveal the presence of a
potent suppressive CD4þFoxp3 T-cell population within the
colorectal tumor regulatory landscape. These CD4þLAPþ T
cells, which coexpress CTLA-4, LAG-3, PD-1, CD39, CD25,
CD103, and Ki67, appear to be highly activated, divide easily
both in vivo and in vitro, and are distinct from the regulatory
populations found in healthy colon and peripheral blood. A
recent paper by Donkor et al.51 demonstrated that tumor
growth and metastasis could be blocked by increased cytotoxic
T cell activity, but that the failure of immune protection
involved TGF-b-mediated suppression of tumor antigen-
specific T-cell responses. Most compellingly, the major source
of TGF-b was the T cells themselves, rather than either the
tumor cells orCD4þFoxp3þ Tregs.Wehave identified amajor
regulatory subset of TILs that does not require Foxp3 for
suppression, but instead expresses TGF-b and IL-10, the two
key regulatory cytokines. Functional analyses revealed that
both these cytokines play a substantial role in the immuno-
suppressive capabilities of tumor-derived CD4þLAPþ T cells,
exerting suppressive activities in vitro that were at least 50-fold
more potent than ‘‘conventional’’ CD4þCD25hiCD127lo
Tregs. Although preventing cell contact between peripheral
blood-derived Foxp3þ Tregs and responder T cells abrogates
their suppressive function (Figure 6c and as previously
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described52), no such effect was observed with CD4þLAPþ
TILs; hence, it is the production and release of inhibitory
cytokines that mediates suppression by this T cell subset rather
than cell contact-dependent mechanisms. In addition, the lack
of cell death found upon stimulation of CFSE-labeled effector T
cells over the course of a 72-h in vitro suppression assay argues
against cytotoxicity as a major mechanism of suppression by
CD4þLAPþ TILs (data not shown). Tumor-infiltrating
CD4þLAPþ T cells therefore represent a subset functionally
distinct from Foxp3þ Tregs derived from peripheral blood.39
The limited numbers of CD4þLAPþ T cells isolated from
small colorectal cancer specimens prohibited an investigation of
the effects of this suppressive T cell subset on CD8þ CTL.
However, as both IL-10 and TGF-b have been shown to limit the
cytotoxic activity of CD8þ CTL, it is likely that CD4þLAPþ T
cells also suppress this important antitumor effector function.
Overall, the data presented in this study indicate that the CD4þ
LAPþ T-cell population likely controls antitumor immune
responses in the local environment, even in the face of systemic
antitumor responses present during the early stages of colorectal
tumor development. Thus, therapeutic strategies that aim to
overcome Treg activity as a means of enhancing antitumor
immune responses need to take into account this novel
intratumoral subset of highly suppressive CD4þFoxp3 T cells.
METHODS
Sample groups. Peripheral blood, colorectal tumor, and paired
background (unaffected) colon specimens were obtained from 40
patients undergoing primary tumor resection for colorectal adeno-
carcinoma at the University Hospital of Wales, Cardiff. Patient char-
acteristics are shown in Table 4. Blood samples were collected no more
than 7 days before surgery. Autologous colon samples were cut from a
macroscopically normal section of the excised tissue, at least 10 cm from
the tumor. All fresh tumor sampleswere derived from the luminal aspect
of the specimen, so as not to interfere with the deep part of the tumor
required for histopathological staging. Peripheral blood samples from
age-matched non-tumor-bearing donors were used as controls.
Informed consent was obtained from all participants. The Bro Taf
Local Research Ethics Committee granted ethical approval for this study.
Lymphocyte extraction. PBMCs were isolated by centrifugation over
Lymphoprep (Axis-Shield, Dundee, Scotland, UK). Background colon
and tumor specimens were transported and washed in extraction
medium comprising Iscove’s modified Dulbecco’s medium supple-
mentedwith penicillin, streptomycin, and L-glutamine (Gibco, Paisley,
UK), 2% human AB serum (Welsh Blood Service, Pontyclun, UK),
20 mgml 1 gentamicin (Invitrogen, Paisley, UK), and 2 mgml 1
fungizone (Invitrogen). Within 30min of resection from a patient,
samples were minced with blades in a Petri dish and forced through
70 mm cell strainers to collect a single-cell suspension. In no instances
were collagenase or DNase treatments used. Cells were centrifuged
twice in extraction medium, then lymphocytes were isolated over a
discontinuous Ficoll gradient as described previously.53 The lympho-
cyte layer was aspirated and washed a further two times before use.
Flow cytometry. Clusters of antibodies were split into four panels for
staining, each comprising a core panel of CD4, CD25, Foxp3, and a
viability dye alongside four other monoclonal antibodies (mAbs). This
approach allowed for coexpression analysis of a large range of
phenotypic markers using a FACSCanto II flow cytometer (BD
Biosciences, Oxford, UK). Samples were resuspended in phosphate-
buffered saline at a concentration of 2–5 106 cells per ml in 96-well
plates (Nunc, Dorset, UK). Cells were initially stained with the amine-
reactive viability dye Live/Dead fixableAqua (Invitrogen) for 15min in
the dark at room temperature. Subsequently, cells werewashed twice in
FACS buffer (phosphate-buffered saline and 2% bovine serum
albumin), and then resuspended in 30 ml FACS buffer for surface
marker staining. The directly conjugated mAbs listed in
Supplementary Table S1 were applied in various combinations and
allowed to incubate for 20min in the dark at 4 1C. Following twomore
wash steps with FACS buffer, cells were permeabilized and fixed using
a Fixation/Permeabilization kit (eBioscience, Hatfield, UK), and
incubated for 40min at 4 1C. Cells were then washed using 1
Permeabilization buffer, and Fc receptors were blocked using rat
serum for 15min at 4 1C. Directly conjugated mAbs specific for
intracellular markers (Supplementary Table S1 online) were then
added in various combinations and allowed to incubate for 30min in
the dark at 4 1C. The cells were then washed once with Permea-
bilization buffer and fixed in phosphate-buffered saline containing 1%
paraformaldehyde (Sigma-Aldrich, Dorset, UK). Fixed cells were
stored in the dark at 4 1C until acquisition. Data were analyzed using
FlowJo software version 9.4 (TreeStar, Ashland, OR) and gates were
drawn based on FMO (fluorescence minus one) controls.
In some instances, cells were additionally stimulated with 20 nM
phorbol 12-myristate 13-acetate (Sigma-Aldrich) and 1 mgml 1
ionomycin (Sigma-Aldrich) for 4 h at 37 1C. After 1 h, 1 ml ml 1
GolgiStop (containing monensin; BD Biosciences) was added.
Intracellular cytokine staining was conducted using directly con-
jugated mAbs specific for IL-10, IL-17A, interferon-g, and TGF-b
(Supplementary Table S1).
Cell sorting. For functional studies, PBMCs were sorted into effector
(CD4þCD25 ) and regulatory (CD4þCD25hiCD127lo) T-cell
Table 4 Characteristics of the colorectal cancer patients
included in this study
Male Female
n 26 14
Age (range) 69 (38–86) 77 (49–88)
Tumor location (%)
Ascending 2 (8) 7 (50)
Transverse 0 (0) 1 (7)
Descending 1 (4) 1 (7)
Sigmoid 8 (31) 4 (29)
Rectum 15 (58) 1 (7)
TNM stage, 5th edition (%)
T1 3 (12) 2 (14)
T2 8 (31) 3 (21)
T3 13 (50) 7 (50)
T4 2 (8) 2 (14)
(Lymph node spread)
N0 18 (69) 8 (57)
N1 6 (23) 2 (14)
N2 2 (8) 4 (29)
Dukes’ stage (%)
A 10 (38) 3 (21)
B 8 (31) 5 (36)
C1 8 (31) 3 (21)
C2 0 (0) 3 (21)
D 0 (0) 0 (0)
TNM, tumor node metastasis.
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subsets using the mAbs listed above. Various CD4þ T-cell subsets
were sorted from colon and tumor specimens using a modified
FACSAria II flow cytometer (BD Biosciences). The gating strategy is
detailed in Supplementary Figures S5B and S5C. Lymphocyte purity
in post-sort analyses was always 495%.
3H-thymidine incorporation assays. T cells were plated in triplicate
on a 96-well plate (Nunc) and cultured in OpTmizer CTS medium
(Invitrogen) supplemented with penicillin, streptomycin, and L-gluta-
mine for 3 days at 37 1C in a 5% CO2 atmosphere. Stimulation was
conducted using Dynabeads Human T-Activator CD3/CD28 (Invi-
trogen) in abead toeffector cell ratio of 1:2. IrradiatedautologousPBMCs
were added as necessary to ensure that overall cell numbers in each assay
were consistent. Cells were then pulsed with 3H-thymidine (1mCI per
well;GEHealthcare, Little Chalfont,UK) for 6 h and harvested onto filter
mats using a TomTec (Hamden, CT) Cell Harvester. Proliferation was
measured as a function of tritiated hydrogen incorporation.
CFSE/PKH-26-based suppression assays. The in vitro function of
actively proliferating FACS-purified T-cell subsets was analyzed by
labeling autologous effector CD4þCD25CD127hi T cells with 0.5mM
CFSE (Invitrogen) and potential regulatory subsets with 2 mM PKH-26
(Sigma-Aldrich). To assess the impact of isolated TIL subsets on
effector T-cell proliferation, cells were coincubated in 96-well plates at
various ratios and stimulated with Dynabeads Human T-Activator
CD3/CD28 (Invitrogen) in a bead to effector cell ratio of 1:2. In some
instances, blocking antibodies to TGF-b (1D11, final concentration
10 mgml 1) or IL-10R (polyclonal; R&D Systems, Abingdon, UK,
final concentration 20 mgml 1) were added directly to the cell
cultures. Transwell experiments were also performed using 0.4 mm
pore-sized inserts in a 96-well permeable support system (Corning,
Lowell, MA) to separate isolated T-cell subsets from CFSE-labeled
responder cells. After 3 days, cells were harvested and acquired using a
FACSCanto II flow cytometer (BD Biosciences). Proliferation of T-cell
subsetswas analyzed by conventional gating and the division indexwas
calculated using the proliferation platform in FlowJo software version
9.4 (TreeStar) as described previously.54
Statistical and graphical analysis. GraphPad Prism Version 5 was
used for all statistical analyses. All results are expressed as mean values
together with the s.e.m. where appropriate. Paired t-tests were used to
compare data obtained from matched blood, colon, and tumor tissue
from the same patient. Unpaired t-tests were used for all other
comparisons.
Analysis and presentation of T-cell subset distributions
were performed using SPICE version 5.1, downloaded from
http://exon.niaid.nih.gov.55
SUPPLEMENTARYMATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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